Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Local and distributed PiB accumulation associated with development of preclinical Alzheimer's disease.

Brier MR, McCarthy JE, Benzinger TLS, Stern A, Su Y, Friedrichsen KA, Morris JC, Ances BM, Vlassenko AG.

Neurobiol Aging. 2016 Feb;38:104-111. doi: 10.1016/j.neurobiolaging.2015.10.025. Epub 2015 Oct 31.

2.

Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.

Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL; AIBL Research Group.

Brain. 2012 Jul;135(Pt 7):2126-39. doi: 10.1093/brain/aws125. Epub 2012 May 23.

PMID:
22628162
3.

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease.

Kadir A, Marutle A, Gonzalez D, Schöll M, Almkvist O, Mousavi M, Mustafiz T, Darreh-Shori T, Nennesmo I, Nordberg A.

Brain. 2011 Jan;134(Pt 1):301-17. doi: 10.1093/brain/awq349. Epub 2010 Dec 13.

4.

Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly.

Sheline YI, Raichle ME, Snyder AZ, Morris JC, Head D, Wang S, Mintun MA.

Biol Psychiatry. 2010 Mar 15;67(6):584-7. doi: 10.1016/j.biopsych.2009.08.024. Epub 2009 Oct 14.

5.

Within-patient correspondence of amyloid-β and intrinsic network connectivity in Alzheimer's disease.

Myers N, Pasquini L, Göttler J, Grimmer T, Koch K, Ortner M, Neitzel J, Mühlau M, Förster S, Kurz A, Förstl H, Zimmer C, Wohlschläger AM, Riedl V, Drzezga A, Sorg C.

Brain. 2014 Jul;137(Pt 7):2052-64. doi: 10.1093/brain/awu103. Epub 2014 Apr 26.

6.

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND, Lopresti BJ, Ziolko S, Bi W, Paljug WR, Debnath ML, Hope CE, Isanski BA, Hamilton RL, DeKosky ST.

Brain. 2008 Jun;131(Pt 6):1630-45. doi: 10.1093/brain/awn016. Epub 2008 Mar 12.

7.

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Ikonomovic MD, Abrahamson EE, Price JC, Hamilton RL, Mathis CA, Paljug WR, Debnath ML, Cohen AD, Mizukami K, DeKosky ST, Lopez OL, Klunk WE.

Acta Neuropathol. 2012 Mar;123(3):433-47. doi: 10.1007/s00401-012-0943-2. Epub 2012 Jan 24.

8.

Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.

Vlassenko AG, McCue L, Jasielec MS, Su Y, Gordon BA, Xiong C, Holtzman DM, Benzinger TL, Morris JC, Fagan AM.

Ann Neurol. 2016 Sep;80(3):379-87. doi: 10.1002/ana.24719. Epub 2016 Jul 25.

9.

The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly.

Wirth M, Oh H, Mormino EC, Markley C, Landau SM, Jagust WJ.

Alzheimers Dement. 2013 Nov;9(6):687-698.e1. doi: 10.1016/j.jalz.2012.10.012. Epub 2013 Mar 7.

10.

White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease?

Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, Guzman VA, Meier IB, Zimmerman ME, Brickman AM; Alzheimer's Disease Neuroimaging Initiative.

JAMA Neurol. 2013 Apr;70(4):455-61. doi: 10.1001/jamaneurol.2013.1321.

11.

Characterizing regional correlation, laterality and symmetry of amyloid deposition in mild cognitive impairment and Alzheimer's disease with Pittsburgh Compound B.

Raji CA, Becker JT, Tsopelas ND, Price JC, Mathis CA, Saxton JA, Lopresti BJ, Hoge JA, Ziolko SK, DeKosky ST, Klunk WE.

J Neurosci Methods. 2008 Jul 30;172(2):277-82. doi: 10.1016/j.jneumeth.2008.05.005. Epub 2008 May 16.

12.

Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.

Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Långström B, Nordberg A.

Brain. 2006 Nov;129(Pt 11):2856-66. Epub 2006 Jul 19.

PMID:
16854944
13.

Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.

Shin J, Lee SY, Kim SJ, Kim SH, Cho SJ, Kim YB.

Neuroimage. 2010 Aug 15;52(2):488-96. doi: 10.1016/j.neuroimage.2010.04.013. Epub 2010 Apr 10.

PMID:
20385246
14.

Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression.

Beckett TL, Webb RL, Niedowicz DM, Holler CJ, Matveev S, Baig I, LeVine H 3rd, Keller JN, Murphy MP.

J Alzheimers Dis. 2012;32(1):127-38.

15.

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.

Trzepacz PT, Yu P, Sun J, Schuh K, Case M, Witte MM, Hochstetler H, Hake A; Alzheimer's Disease Neuroimaging Initiative.

Neurobiol Aging. 2014 Jan;35(1):143-51. doi: 10.1016/j.neurobiolaging.2013.06.018. Epub 2013 Aug 15.

PMID:
23954175
16.

Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)-PK11195 positron emission tomographic imaging in Alzheimer disease.

Wiley CA, Lopresti BJ, Venneti S, Price J, Klunk WE, DeKosky ST, Mathis CA.

Arch Neurol. 2009 Jan;66(1):60-7. doi: 10.1001/archneurol.2008.511.

17.

Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.

Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE.

J Neurol Neurosurg Psychiatry. 2012 Sep;83(9):923-6. doi: 10.1136/jnnp-2012-302548. Epub 2012 Jul 11.

18.

11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment.

Jack CR Jr, Lowe VJ, Senjem ML, Weigand SD, Kemp BJ, Shiung MM, Knopman DS, Boeve BF, Klunk WE, Mathis CA, Petersen RC.

Brain. 2008 Mar;131(Pt 3):665-80. doi: 10.1093/brain/awm336. Epub 2008 Feb 7.

19.

Comparison of MR-less PiB SUVR quantification methods.

Bourgeat P, Villemagne VL, Dore V, Brown B, Macaulay SL, Martins R, Masters CL, Ames D, Ellis K, Rowe CC, Salvado O, Fripp J; AIBL Research Group.

Neurobiol Aging. 2015 Jan;36 Suppl 1:S159-66. doi: 10.1016/j.neurobiolaging.2014.04.033. Epub 2014 Aug 27.

PMID:
25257985
20.

Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum.

Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR Jr, Dickson DW.

Brain. 2015 May;138(Pt 5):1370-81. doi: 10.1093/brain/awv050. Epub 2015 Mar 23.

Supplemental Content

Support Center